Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355 million; shares edge higher | Stock Market News
Source: Live Mint Sun Pharmaceutical Industries Ltd. has announced the acquisition of Nasdaq-listed Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company, in a $355 million cash deal. The acquisition will bolster Sun Pharma’s onco-dermatology portfolio, adding Checkpoint’s recently FDA-approved cancer drug, UNLOXCYT (cosibelimab-ipdl), to its pipeline. The deal, expected to close in the second…
